Debra K. Bowes, MBEE

Debra K. Bowes, MBEE

Chief Business Officer (CBO)

With 30 years of biotech/pharma experience, Debra recently accepted the position of Chief Business Officer for Luminary. She is also a cell therapy advisor for Harrington Discovery Institute as well as Case Western Reserve University. previously served as Chief Business Officer, Cell Therapies for MaxCyte CARMA, where she built the drug development team, filed the company’s first cell therapy IND and initiated their first clinical trial.

In addition, she negotiated and closed 3 cell therapy platform licenses with notable cell therapy companies.

Debra founded Chevy Chase BioPartners in 2006 a consulting firm specializing in Commercial Strategic Planning and Licensing for biotech/pharmaceutical companies. During this time she held contract positions as interim CEO for CapGenesis Therapeutics and VP of Licensing and Commercial Strategy for CBLI Pharma. Prior to starting CCBP she was the Sr Director of New Product Planning for MedImmune where she built a department responsible for supporting the strategic business planning aspects of MedImmune’s R&D pipeline. Prior to MedImmune Debra held the position of Senior Director, Corporate Development for Amylin Pharmaceuticals. Previously, she spent several years at Pfizer Pharmaceuticals in Licensing and New Product Planning focusing on oncology. Serving as Worldwide Market Manager for Centocor, she was responsible for managing and expanding oncology licensing agreements with European and Asian partners. Debra started her pharmaceutical career with Hybritech, Inc where she held positions of growing responsibility in sales, marketing, market research and licensing.

Debra is a former National President, current National Board Member and member of Nat’l Director Emeritus for Women in BIO. She has been an industry speaker since 2005 and currently serves on Industry Corporate Boards. Debra holds a Bachelor of Science degree in cell biology from the University of Cincinnati, a Medical Technologist (M.T.) certification from the American Society of Clinical Pathologists and an MBEE from John’s Hopkins University.